1 study found for:    EC-FV-06
Show Display Options
Rank Status Study
1 Recruiting Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Condition: Ovarian Cancer
Interventions: Drug: EC145;   Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®);   Drug: placebo;   Drug: EC20

Indicates status has not been verified in more than two years